Rallybio Corp (RLYB) stock
RLYBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/30
$15.29−0.14 (-0.88%)
Close on Nov 17, 2026Market cap $82.32MP/E 3.4Yield –
Rallybio EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Rallybio's EPS for the twelve months ending Sep 30, 2026 was $4.56. For fiscal 2025 it was -$1.59. The highest annual figure on record is -$1.59 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.59 | – |
| FY2024 | Dec 31, 2024 | -$10.61 | – |
| FY2023 | Dec 31, 2023 | -$14.72 | – |
| FY2022 | Dec 31, 2022 | -$16.72 | – |
| FY2021 | Dec 31, 2021 | -$14.72 | – |
| FY2020 | Dec 31, 2020 | -$12.16 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.48 | -116.9% |
| Q2 FY2026 | Jun 30, 2026 | $7.53 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.46 | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.03 | – |
| Q3 FY2025 | Sep 30, 2025 | $2.84 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.76 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.69 | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.98 | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.08 | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.96 | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.76 | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.98 | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.60 | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.68 | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.44 | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.64 | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.80 | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.56 | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.84 | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.31 | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.96 | – |
| Q2 FY2021 | Jun 30, 2021 | -$3.92 | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.80 | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.78 | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.56 | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.37 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?